StreetInsider.com News Articles

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

72 patient multi-indication trial approved to fast track TRP-8803 commercialisation

Tue, 04 Aug 2026 10:00:00 -0400

Human Research Ethics Committee (HREC) approval secured for world-first phase 1b/2a 8-indication basket study across in 72-patients of TRP-8803
Study will evaluate TRP-8803 (IV-infused psilocin) across eight major disorders with high unmet treatment needs in a single clinical framework
Study indications include Anorexia Nervosa, Body Dysmorphic Disorder, Obsessive Compulsive Disorder, Generalised Anxiety Disorder, Post Traumatic Stress Disorder, Treatment-Resistant Depression, Fibromyalgia and Irritable Bowel Syndrome
Treatment-Resistant Depression to be evaluated across two distinct patient cohorts with one cohort on antidepressant therapy and another off
All indications selected for their strong scientific rationale and growing clinical evidence supporting the therapeutic potential of TRP-8803
New Clinical

ENPAR Technologies Inc. Name and Ticker Symbol Change

Tue, 02 Jan 2018 08:00:00 -0400
si-local-file:///var/storage/newsbody/2018/0102/13641733.html

ENPAR Technologies Inc. Name and Ticker Symbol Change

Tue, 02 Jan 2018 08:00:00 -0400
si-local-file:///var/storage/newsbody/2018/0102/13641733.html

First Tranche of Private Placement of up to $5,000,000

Mon, 18 Dec 2017 10:53:00 -0400
si-local-file:///var/storage/newsbody/2017/1218/13610199.html

First Tranche of Private Placement of up to $5,000,000

Mon, 18 Dec 2017 10:53:00 -0400
si-local-file:///var/storage/newsbody/2017/1218/13610199.html

First Tranche of Private Placement of up to $5,000,000

Fri, 15 Dec 2017 13:35:00 -0400
si-local-file:///var/storage/newsbody/2017/1215/13606266.html

First Tranche of Private Placement of up to $5,000,000

Fri, 15 Dec 2017 13:35:00 -0400
si-local-file:///var/storage/newsbody/2017/1215/13606266.html

The Closing Date to Acquire Pumptronics Incorporated has Been Extended to December 28, 2017

Thu, 30 Nov 2017 12:10:00 -0400
si-local-file:///var/storage/newsbody/2017/1130/13555981.html

The Closing Date to Acquire Pumptronics Incorporated has Been Extended to December 28, 2017

Thu, 30 Nov 2017 12:10:00 -0400
si-local-file:///var/storage/newsbody/2017/1130/13555981.html

ENPAR Technologies Inc. to Acquire Pumptronics Incorporated

Tue, 10 Oct 2017 13:14:00 -0400
si-local-file:///var/storage/newsbody/2017/1010/13376636.html

ENPAR Technologies Inc. to Acquire Pumptronics Incorporated

Tue, 10 Oct 2017 13:14:00 -0400
si-local-file:///var/storage/newsbody/2017/1010/13376636.html

ENPAR Closes Private Placement

Thu, 28 Sep 2017 08:50:00 -0400
si-local-file:///var/storage/newsbody/2017/0928/13337287.html

ENPAR Closes Private Placement

Thu, 28 Sep 2017 08:50:00 -0400
si-local-file:///var/storage/newsbody/2017/0928/13337287.html

ENPAR Technologies Inc.: Private Placement of up to $350,000

Mon, 18 Sep 2017 08:36:00 -0400
si-local-file:///var/storage/newsbody/2017/0918/13303756.html

ENPAR Technologies Inc.: Private Placement of up to $350,000

Mon, 18 Sep 2017 08:36:00 -0400
si-local-file:///var/storage/newsbody/2017/0918/13303756.html

ENPAR to Be Featured on CEO Clips on BNN

Fri, 14 Jul 2017 13:19:00 -0400
si-local-file:///var/storage/newsbody/2017/0714/13099416.html

ENPAR to Be Featured on CEO Clips on BNN

Fri, 14 Jul 2017 13:19:00 -0400
si-local-file:///var/storage/newsbody/2017/0714/13099416.html

Dr. Gene Shelp Presents at Pujiang Innovation Forum 2017 - Canada Forum - Emerging Industrial Water Treatment Sector

Wed, 24 May 2017 08:00:00 -0400
si-local-file:///var/storage/newsbody/2017/0524/12940063.html